



ImmuPharma PLC
("ImmuPharma" or the "Company")

Grant of Share Options & PDMR dealing

ImmuPharma PLC (LSE:IMM | Euronext Growth: ALIMM), the specialist drug discovery and development company, announces the approval of the grant of options over a total of 9,625,000 ordinary shares of 10p each in the Company ("Ordinary Shares") to Directors, employees and consultants representing 3.8% of ImmuPharma's Ordinary Shares and total voting rights (the "Options"). ImmuPharma currently has 250,221,297 Ordinary Shares in issue.

Upon the recommendation of the Company's remuneration committee, the Company has granted the Options pursuant to the Company's Share Option Plan which was adopted on 30 March 2017 (the "2017 Plan").

The exercise price for the Options is 20p being a 54% premium to the closing middle market share price of 13p on 25 November 2020. The Options will vest after three years and are exercisable between three and ten years from the date of grant.

The amount of Options granted to the Directors are summarised in the following table:

Director	Options Granted
Dimitri Dimitriou	1,500,000
Dr Robert Zimmer	1,875,000*
Tim McCarthy	1,500,000
Dr Franco di Muzio	300,000
Dr Stephane Mery	300,000

*Includes 375,000 Options granted to Elizabeth Zimmer, Robert Zimmer's wife who is also an employee of the Company

Following the grant of Options, the Directors will have the following interests in share options in the Company:

Director	Number of options	Exercise Price	Expiry Date
Dimitri Dimitriou	1,000,000	50.25p	30.03.2027
	1,500,000	98.62p	24.11.2027
	1,500,000	20.00p	26.11.2030
Dr Robert Zimmer	50,000*	90.75p	24.11.2021
	100,000*	43.88p	02.06.2026
	1,250,000*	50.25p	30.03.2027
	1,875,000*	98.62p	24.11.2027
	1,875,000*	20.00p	26.11.2030
Tim McCarthy	500,000	43.88p	02.06.2026
	1,000,000	56.75p	12.07.2027
	1,500,000	98.62p	24.11.2027
	1,500,000	20.00p	26.11.2030
Dr Franco di Muzio	100,000	43.88p	02.06.2026
	200,000	56.75p	12.07.2027
	300,000	98.62p	24.11.2027
	300,000	20.00p	26.11.2030
Dr Stephane Mery	100,000	43.88p	02.06.2026
	200,000	56.75p	12.07.2027
	300,000	98.62p	24.11.2027
	300,000	20.00p	26.11.2030

*Includes Options granted to Elizabeth Zimmer, Robert Zimmer's wife who is also an employee of the Company

The Directors currently have the following interests in Ordinary Shares:

Director	Number of Ordinary Shares	% of issued share capital at 25 November 2020
Dimitri Dimitriou	3,567,430	1.45%
Dr Robert Zimmer	27,344,514*	11.10%
Tim McCarthy	38,462	0.01%
Dr Franco di Muzio	99,412	0.04%
Dr Stephane Mery	21,490	0.01%

*includes 22,000,000 shares held by Luca & Associates AG, an entity connected with Dr Zimmer, and of which he is President and a shareholder.

Other grants of Options to Persons Discharging Managerial Responsibilities (“PDMR”)

1,500,000 Options have been granted to Tim Franklin, Chief Operating Officer of the Company. Following the grant of these Options, Tim Franklin will hold Options over 1,500,000 Ordinary Shares in the Company. Similarly, 375,000 Options have been granted to Ewa Flynn, Financial Controller of the Company. Following the grant of these Options, Ewa Flynn will hold Options over 375,000 Ordinary Shares in the Company. Neither Dr Franklin nor Ewa Flynn currently hold any interests in Ordinary Shares in the Company.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1	Details of the person discharging managerial responsibilities / person closely associated		
a)	Name	Dimitri Dimitriou	
2	Reason for the notification		
a)	Position/status	Chief Executive Officer	
b)	Initial notification /Amendment	Initial notification	
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	ImmuPharma PLC	
b)	LEI	213800VZKGHXC7VUS895	
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument, type of instrument	Ordinary Shares of 10p each	
	Identification code	ISIN: GB0033711010	
b)	Nature of the transaction	Grant of share options over Ordinary Shares	
c)	Price(s) and volume(s)	Price	Volume

		Exercise price: 20p per Ordinary Share	1,500,000
d)	Aggregated information - Aggregated volume - Price	N/A	
e)	Date of the transaction	25 November 2020	
f)	Place of the transaction	Off market	

1	Details of the person discharging managerial responsibilities / person closely associated		
a)	Name	Dr Robert Zimmer	
2	Reason for the notification		
a)	Position/status	President & Chief Scientific Officer	
b)	Initial notification /Amendment	Initial notification	
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	ImmuPharma PLC	
b)	LEI	213800VZKGHXC7VUS895	
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of 10p each ISIN: GB0033711010	
b)	Nature of the transaction	Grant of share options over Ordinary Shares	
c)	Price(s) and volume(s)	Price	Volume
		Exercise price: 20p per Ordinary Share	1,875,000 (includes 375,000 to Elizabeth Zimmer)
d)	Aggregated information - Aggregated volume - Price	N/A	

e)	Date of the transaction	25 November 2020
f)	Place of the transaction	Off market

1	Details of the person discharging managerial responsibilities / person closely associated	
a)	Name	Tim McCarthy
2	Reason for the notification	
a)	Position/status	Non-Executive Chairman
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	ImmuPharma PLC
b)	LEI	213800VZKGHXC7VUS895
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of 10p each ISIN: GB0033711010
b)	Nature of the transaction	Grant of share options over Ordinary Shares
c)	Price(s) and volume(s)	Price
		Volume
		Exercise price: 20p per Ordinary Share
		1,500,000
d)	Aggregated information - Aggregated volume - Price	N/A
e)	Date of the transaction	25 November 2020
f)	Place of the transaction	Off market

1	Details of the person discharging managerial responsibilities / person closely associated	
a)	Name	Dr Franco Di Muzio
2	Reason for the notification	

a)	Position/status	Non-Executive Director	
b)	Initial notification /Amendment	Initial notification	
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	ImmuPharma PLC	
b)	LEI	213800VZKGHXC7VUS895	
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of 10p each ISIN: GB0033711010	
b)	Nature of the transaction	Grant of share options over Ordinary Shares	
c)	Price(s) and volume(s)	Price	Volume
		Exercise price: 20p per Ordinary Share	300,000
d)	Aggregated information - Aggregated volume - Price	N/A	
e)	Date of the transaction	25 November 2020	
f)	Place of the transaction	Off market	

1	Details of the person discharging managerial responsibilities / person closely associated		
a)	Name	Dr Stéphane Méry	
2	Reason for the notification		
a)	Position/status	Non-Executive Director	
b)	Initial notification /Amendment	Initial notification	
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	ImmuPharma PLC	
b)	LEI	213800VZKGHXC7VUS895	

4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of 10p each ISIN: GB0033711010	
b)	Nature of the transaction	Grant of share options over Ordinary Shares	
c)	Price(s) and volume(s)	Price	Volume
		Exercise price: 20p per Ordinary Share	300,000
d)	Aggregated information - Aggregated volume - Price	N/A	
e)	Date of the transaction	25 November 2020	
f)	Place of the transaction	Off market	

PDMR Options

1	Details of the person discharging managerial responsibilities / person closely associated		
a)	Name	Dr Tim Franklin	
2	Reason for the notification		
a)	Position/status	Chief Operating Officer	
b)	Initial notification /Amendment	Initial notification	
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	ImmuPharma PLC	
b)	LEI	213800VZKGHXC7VUS895	
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of 10p each ISIN: GB0033711010	

b)	Nature of the transaction	Grant of share options over Ordinary Shares	
c)	Price(s) and volume(s)	Price	Volume
		Exercise price: 20p per Ordinary Share	1,500,000
d)	Aggregated information - Aggregated volume - Price	N/A	
e)	Date of the transaction	25 November 2020	
f)	Place of the transaction	Off market	

1	Details of the person discharging managerial responsibilities / person closely associated		
a)	Name	Ewa Flynn	
2	Reason for the notification		
a)	Position/status	Financial Controller	
b)	Initial notification /Amendment	Initial notification	
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	ImmuPharma PLC	
b)	LEI	213800VZKGHXC7VUS895	
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument, type of instrument	Ordinary Shares of 10p each	
	Identification code	ISIN: GB0033711010	
b)	Nature of the transaction	Grant of share options over Ordinary Shares	
c)	Price(s) and volume(s)	Price	Volume
		Exercise price: 20p per Ordinary Share	375,000
d)	Aggregated information - Aggregated volume	N/A	

	- Price	
e)	Date of the transaction	25 November 2020
f)	Place of the transaction	Off market

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014. ("MAR")

For further information please contact:

ImmuPharma PLC (www.immupharma.com) + 44 (0) 207 152 4080

Tim McCarthy, Chairman

Dimitri Dimitriou, Chief Executive Officer

Lisa Baderoon, Head of Investor Relations

+ 44 (0) 7721 413496

SPARK Advisory Partners Limited (NOMAD)

Neil Baldwin

+44 (0) 203 368 3550

Stanford Capital Partners (Joint Broker)

Patrick Claridge

John Howes

Bob Pountney

+44 (0) 203 815 8880

+44 (0) 1483 413500

SI Capital (Joint Broker)

Nick Emerson

4Reliance (Euronext Growth Listing Sponsor)

Jean-Charles Snoy

+32 (0) 2 747 02 60

Degroof Petercam (Liquidity Provider)

Erik De Clippel

+32 (0) 2 287 95 34

Backstage Communication

Olivier Duquaine

Gunther De Backer

+32 (0) 477 504 784

+32 (0) 475 903 909

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM – Euronext Growth: ALIMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases, anti-infectives, metabolic diseases and cancer. The lead program, Lupuzor™, is a first-in class autophagy immunomodulator which is in Phase III for the treatment of systemic lupus erythematosus (lupus / SLE). Lupus is an autoimmune disease which if left untreated can be fatal. Preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same

autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on 28 November 2019, an exclusive licence and development agreement and trademark agreement for Lupuzor™ to fund a new international Phase III trial for Lupuzor™ and commercialise in the US.

For additional information about ImmuPharma please visit www.immupharma.com.

ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.